Chlorin photosensitizer photolysis products for treating hospital-acquired pneumonia

Y. Alekseev, V. S. Shiriaev, A. Baranov, A. Khosrovyan, V. Babushkin
{"title":"Chlorin photosensitizer photolysis products for treating hospital-acquired pneumonia","authors":"Y. Alekseev, V. S. Shiriaev, A. Baranov, A. Khosrovyan, V. Babushkin","doi":"10.37895/2071-8004-2023-27-1-16-22","DOIUrl":null,"url":null,"abstract":"Purpose: to develop a technique for therapeutic application of photoactivated photosensitizer «Radachlorin» to be included into the complextherapy of nosocomial pneumonia.Material and methods. Twelve patients with nosocomial pneumonia were taken in the trial. They were treated with a device having a nebulizer witha ring-shaped irradiator and diodes λ ≈ 660 nm for photoactivation of photosensitizer «Radachlorin» (manufactured by OOO «RADA-PHARMA»,Moscow, registration number LS-001868). The photosensitizer was developed according to the technical tasks provided by OOO «New SurgicalTechnologies» (Moscow, Russia). Radachlorin solution photolysis products were inhaled by the patients twice a day for 3 days in combinationwith the standard therapy when they were in ICU. Patients in the control group (n = 12) did not have any inhalations.Results and discussion. On day 3, the number of colony-forming units (CFU) of various pathogens found in swabs from the throat decreasedby 39.45 ± 3.17 % on average; C-reactive protein decreased by 42.38 ± 4.26 %; procalcitonin decreased by 51.83 ± 3.45 %, if to compareto baseline limits. At the same period in the control group, CFU in swabs increased in average by 17.28 ± 4.21 %; C-reactive protein increasedby 27.76 ± 3.52 %; procalcitonin increased by 30.15 ± 2.24 %. On day 10 in the main group, the number of CFU pathogens decreasedby 35.45 ± 3.32 %; C-reactive protein decreased by 72.15 ± 2.56 %; procalcitonin decreased by 55.56 ± 4.23 %, if to compare to baseline limits. On day 10 in the control group, CFU concentration remained elevated by 31.15 ± 2.56 %; C-reactive protein – by 65.32 ± 4.27; procalcitonin – by 30.21 ± 3.45 %, if to compare to baseline values. These findings indicate that the inflammatory process acquired a progressive form which demands switching to other curative modalities and more careful selection of antibiotics. The probability of random origin in statistical processing is p < 0.05. There were no undesirable side effects during procedures.Conclusion. Justified application of the described technique – inhalations of photolysis products of E 6 chloride derivatives – has an effective therapeutic impact at the course of nosocomial pneumonia. It seems promising to continue investigations on the described technique, namely, to search for the most effective ways of its application, to find out an optimal number and frequency of procedures under the control of general clinical and special methods of examination of the studied patients, since the data which have been obtained by the authors us are preliminary and should be supplemented with new findings.","PeriodicalId":10008,"journal":{"name":"中国激光医学杂志","volume":"81 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国激光医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.37895/2071-8004-2023-27-1-16-22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: to develop a technique for therapeutic application of photoactivated photosensitizer «Radachlorin» to be included into the complextherapy of nosocomial pneumonia.Material and methods. Twelve patients with nosocomial pneumonia were taken in the trial. They were treated with a device having a nebulizer witha ring-shaped irradiator and diodes λ ≈ 660 nm for photoactivation of photosensitizer «Radachlorin» (manufactured by OOO «RADA-PHARMA»,Moscow, registration number LS-001868). The photosensitizer was developed according to the technical tasks provided by OOO «New SurgicalTechnologies» (Moscow, Russia). Radachlorin solution photolysis products were inhaled by the patients twice a day for 3 days in combinationwith the standard therapy when they were in ICU. Patients in the control group (n = 12) did not have any inhalations.Results and discussion. On day 3, the number of colony-forming units (CFU) of various pathogens found in swabs from the throat decreasedby 39.45 ± 3.17 % on average; C-reactive protein decreased by 42.38 ± 4.26 %; procalcitonin decreased by 51.83 ± 3.45 %, if to compareto baseline limits. At the same period in the control group, CFU in swabs increased in average by 17.28 ± 4.21 %; C-reactive protein increasedby 27.76 ± 3.52 %; procalcitonin increased by 30.15 ± 2.24 %. On day 10 in the main group, the number of CFU pathogens decreasedby 35.45 ± 3.32 %; C-reactive protein decreased by 72.15 ± 2.56 %; procalcitonin decreased by 55.56 ± 4.23 %, if to compare to baseline limits. On day 10 in the control group, CFU concentration remained elevated by 31.15 ± 2.56 %; C-reactive protein – by 65.32 ± 4.27; procalcitonin – by 30.21 ± 3.45 %, if to compare to baseline values. These findings indicate that the inflammatory process acquired a progressive form which demands switching to other curative modalities and more careful selection of antibiotics. The probability of random origin in statistical processing is p < 0.05. There were no undesirable side effects during procedures.Conclusion. Justified application of the described technique – inhalations of photolysis products of E 6 chloride derivatives – has an effective therapeutic impact at the course of nosocomial pneumonia. It seems promising to continue investigations on the described technique, namely, to search for the most effective ways of its application, to find out an optimal number and frequency of procedures under the control of general clinical and special methods of examination of the studied patients, since the data which have been obtained by the authors us are preliminary and should be supplemented with new findings.
用于治疗医院获得性肺炎的氯光敏剂光解产品
目的:开发一种将光活化光敏剂“达氯林”纳入院内肺炎综合治疗的治疗技术。材料和方法。12例院内肺炎患者参加了试验。他们用一个带有环形辐照器的雾化器和λ≈660 nm二极管的装置进行处理,用于光敏剂“Radachlorin”的光活化(由莫斯科OOO«RADA-PHARMA»制造,注册号LS-001868)。该光敏剂是根据OOO«New SurgicalTechnologies»(莫斯科,俄罗斯)提供的技术任务开发的。患者在ICU期间,在标准治疗的基础上,每日吸入2次达氯溶液光解产物,连用3天。对照组(n = 12)患者无任何吸入。结果和讨论。第3天,咽拭子中各种病原菌菌落形成单位(CFU)平均减少39.45±3.17%;c -反应蛋白降低42.38±4.26%;与基线相比,降钙素原降低51.83±3.45%。同期对照组拭子CFU平均升高17.28±4.21%;c反应蛋白升高27.76±3.52%;降钙素原升高30.15±2.24%。主组第10天CFU病原菌数量减少35.45±3.32%;c -反应蛋白降低72.15±2.56%;与基线相比,降钙素原降低55.56±4.23%。第10天,对照组CFU浓度仍升高31.15±2.56%;c反应蛋白-比65.32±4.27;降钙素原-与基线值相比下降30.21±3.45%。这些发现表明,炎症过程获得了一种进行性形式,需要切换到其他治疗方式和更仔细地选择抗生素。统计处理中随机起源的概率p < 0.05。手术过程中无不良反应。合理应用所描述的技术-吸入e6氯化物衍生物的光解产物-在院内肺炎过程中具有有效的治疗效果。似乎有希望继续对所描述的技术进行研究,即寻找其最有效的应用方法,在研究患者的一般临床检查和特殊检查方法的控制下找出最佳的手术次数和频率,因为作者所获得的数据是初步的,应该补充新的发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
5650
期刊介绍: The main columns of "Chinese Journal of Laser Medicine & Surgery" include treatises, which report the latest research results in basic research and clinical trials in the field of laser medicine; comprehensive reviews of the latest research progress in laser medicine at home and abroad. In addition, there are short reports and excerpts from foreign journals, conference news and other columns. The journal has published a large number of papers on basic research on laser medicine and applied research in various clinical subjects, aiming to play a positive role in promoting the application of laser in medicine and improving the level of laser medicine research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信